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Mycobacterium phenotypic hits are a good reservoir for new chemotypes for the
treatment of tuberculosis. However, the absence of defined molecular targets and
modes of action could lead to failure in drug development. Therefore, a combination of
ligand-based and structure-based chemogenomic approaches followed by biophysical
and biochemical validation have been used to identify targets for Mycobacterium
tuberculosis phenotypic hits. Our approach identified EthR and InhA as targets for several
hits, with some showing dual activity against these proteins. From the 35 predicted
EthR inhibitors, eight exhibited an IC50 below 50 µM against M. tuberculosis EthR and
three were confirmed to be also simultaneously active against InhA. Further hit validation
was performed using X-ray crystallography yielding eight new crystal structures of EthR
inhibitors. Although the EthR inhibitors attain their activity against M. tuberculosis by
hitting yet undefined targets, these results provide new lead compounds that could be
further developed to be used to potentiate the effect of EthA activated pro-drugs, such
as ethionamide, thus enhancing their bactericidal effect.
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INTRODUCTION
The pursuit of new and alternative drugs for the treatment of tuberculosis has led to phenotypic
screens taking center stage in identifying novel and effective drug candidates (Lechartier et al.,
2014). This screening effort has resulted in thousands of bioactive compounds released into the
public databases, by researchers. The open access ChEMBL database (Gaulton et al., 2012, 2016)
houses (as of February 2017) more than 16 datasets containing phenotypic hits for Neglected
Tropical Diseases (https://www.ebi.ac.uk/chemblntd). These include the GSK TCAMS dataset
containing about 776 phenotypic compounds that have shown activity againstMycobacterium bovis
(IC50 < 10 µM), and have exhibited low hepatotoxicity levels (Ballell et al., 2013) in whole-cell
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screening assays. In particular, 177 of these compounds were
found to be non-toxic for HepG2 cells [(HepG2 IC50/MIC)> 50]
and have demonstrated the ability to also highly inhibit the
growth of the related Mycobacterium tuberculosis (MIC against
H37Rv of < 10 µM), the main causative agent of tuberculosis, a
disease affecting about 9 million people every year.
The success of phenotypic hits, in preclinical and clinical
drug development depends to a greater extent, on the
knowledge of their mechanism of action. However, the protein
targets for most of the reported phenotypic hits are still to
be identified. Experimentally identifying targets for all the
phenotypic hits involves a broad range of approaches including
genetic, proteomic, and transcriptional profiling, and more
direct chemical-proteomic methods (Hart, 2005). It is therefore
advantageous, after phenotypic screening to use computational
methods that can predict likely protein targets of a given active
small molecule, providing target-ligand pairs as starting points,
thereby narrowing the search for the target proteins (Szardenings
et al., 2004; Jenkins et al., 2006; Rebollo-Lopez et al., 2015).
In chemogenomics predictive approaches, targets are
proposed by considering the chemical structural features of the
active compounds (Jenkins et al., 2006) available in databases
such as ChEMBL and PubChem BioAssay and comparing
these to features of known ligands of a set of targets. Some of
these approaches include ligand-based 2D chemical similarity
assessment, cluster analysis and the use of 3D descriptors
when the orphan compound has low similarity to all database
molecules (Jenkins et al., 2006; Bender et al., 2007). In addition,
machine-learning methods are also being used to extract
targets and their associated ligands automatically from target-
ligand information stored in multiple-target models. The
multiple-category Laplacian-corrected Naïve Bayesian Classifiers
(MCNBC) trained on extended-connectivity fingerprint of
964 targets classes in the WOMBAT database were originally
described by Nidhi et al. (2006) and have been previously used
(Ekins et al., 2013; Martínez-Jiménez et al., 2013) to identify
targets for the TCAMS anti-TB phenotypic hits. However,
experimental confirmation of the predicted targets for these
compounds is limited and in most instances, still to be reported.
The enoyl-acyl carrier protein reductase (InhA) is a well-
known anti-TB target involved in the biosynthesis of mycolic
acids and is the target of first- and second-line TB drugs,
isoniazid, and ethionamide respectively. The two drugs require
metabolic activation inside M. tuberculosis cells by specific
proteins; the heme enzyme catalase peroxidase (KatG) for
isoniazid, and FAD-containing monooxygenase (EthA) for
ethionamide; interestingly much of the clinically observed
resistance is associated with the drug activation mechanisms
(Takayama et al., 1972; Timmins and Deretic, 2006). Studies
of the resistance mechanism of ethionamide revealed that an
increase in the expression of HTH-Transcriptional regulator,
EthR, reduces transcription and the level of active EthA protein,
and results in resistance by M. tuberculosis (DeBarber et al.,
2000; Dover et al., 2004). The discovery of this transcriptional
regulator led to the notion of controlling EthA expression
levels by targeting EthR and thus boosting the bactericidal
effect of ethionamide (Frenois et al., 2004; Willand et al.,
2009). Therefore, identifying compounds that bind to EthR and
prevent the repression of EthA would not only circumvent
some of the resistance mechanisms but also reduce the required
dosage and therefore the toxicity associated with this drug. In
this work, we report for the first time, inhibitors of two M.
tuberculosis targets, (EthR and InhA), identified using predictive
in silicomethods and definitively confirmed through biophysical
methods, biochemical assays, and X-ray crystallography.
METHODS
Identification of Targets of Anti-TB
Phenotypic Hits
In previous work, we reported a detailed description of the
target prediction protocol (Mugumbate et al., 2015) comprising
of two ligand-based and one structure-based approach to identify
targets for the 776 TCAMS-TB compounds (Ballell et al.,
2013) retrieved from the ChEMBL database (https://www.ebi.
ac.uk/chembl/). The same protocol and models were used in
this work to identify targets for further anti-TB phenotypic
hit compounds; hence a brief description of the ligand-based
method is presented here. The dataset of anti-TB compounds was
prepared using a protocol in Pipeline Pilot version 8.5 (Warr,
2012), by generating 2D coordinates for each compound, and
standardizing stereochemistry, and formal charges for common
functional groups. In addition, salts and single atom were
removed.
Ligand-Based Target Identification
A dataset containing 698,401 human and bacterial target-ligand
pairs was extracted from ChEMBL version 17 (http://www.ebi.ac.
uk/ChEMBL). The dataset contained targets with an annotated
ChEMBL confidence score (CS) ranging from 7 to 9, indicating
that the target—ligand pairs have unambiguously defined protein
complexes or single proteins. Filtering the dataset to collect
targets with 10 or more annotated ligands that exhibited IC50,
EC50, or Ki values ≤ 10 µM or inhibition ≥ 50% against their
respective targets resulted in a total of 2,257 unique human and
bacterial proteins,. Amongst these were 50 proteins belonging to
the pathogenic bacterial species,M. tuberculosis. Human proteins
were included to enable identification of potential host off-targets
for the anti-tuberculosis compounds. MCNBCs were generated
by training the protein identifiers on the structural features
of their compounds, defined by their extended-connectivity
fingerprint of diameter 6 (ECFP_6) (Rogers and Hahn, 2010) in
Pipeline Pilot.
We determined the robustness of our models by a guaranteed
random selection of compounds for both the training and test
sets and minimized bias by presenting the model with a test set of
previously unseen compounds using two methods (Supporting
Information). In both instances the models displayed 75–90%
accuracy, quantified by the percentage of compounds with
correctly assigned targets reported in ranked positions 1–5.
During the production stage, a model MCNBC trained on
695,902 target-ligand pairs was used to identify targets for all
776 phenotypic hits. We retained pairs of targets and compounds
with positive Bayesian (NB)-scores and Z-scores ≥ 1.5. The
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Bayesian Score is defined as the sum (Ptotal) of the logarithm
of Laplacian-corrected Bayes rule of conditional probability
[P(A|Fi)] for each fingerprint feature of a compound (12, 21).
The Z-score distinguishes the compound scores for a particular
target from the influence of the background noise. The score
was obtained by predicting targets for > 1,200,000 compounds
in ChEMBL version 17 database and generated the background
information by calculate mean NB scores (µ) and standard
deviation (σ) for each target. For each predicted target, standard
scores (Z-score) were calculated from a statistical analysis of the
NB scores for each compound: Z-score = (X − µ)/σ where, X
is the NB score of a target for a compound. We have similarly
generated Bayesian models using ChEMBL versions 20 and 21
data, however here we report the results obtained using ChEMBL
17 based models used at the time of the study.
These predictions were complemented by utilizing a
second and independent ligand-based approach, The
Similarity Ensemble Approach (SEA), which exploits chemical
similarity between two sets of ligands, was used to study the
pharmacological relationships between drugs (Keiser et al., 2009;
Lounkine et al., 2012) and to predict targets for all 776 GSK
phenotypic hits. At the time of this study the latest version of SEA
utilized ChEMBL version 16 data and extended-connectivity
fingerprint of diameter 4 (ECFP_4) fingerprints. To validate
the method, the tool was used to predict targets for TB drugs
of known modes of action where the bioactivity data are
not found in ChEMBL version 16. We selected predicted M.
tuberculosis protein targets from target-ligand pairs displaying
expectation (E) values < 10−1. In general, the E-value describes
the significance of similarity between an orphan compound and
a set of ligands and is a good indicator for the most likely targets
(Keiser et al., 2007). A cut-off of 10−1 guaranteed selection of all
possible target-ligand pairs and was suitable for our purposes.
Structure-Based Target Identification
The MCNBC and SEA methods provided a set of potential
predicted targets, from which targets to use in structure-based
target identification were selected. The Internal Coordinate
Mechanism (ICM) method developed by Molsoft L.L.C (Totrov
and Abagyan, 1997) was used to estimate the binding affinities
of the anti-TB phenotypic hits to two predicted M. tuberculosis
targets, EthR and InhA, based on the ICM scoring function, and
available structures in wwPDB. The scoring function takes into
consideration the energy changes due to protein-ligand binding
and is defined as:
1G = 1EIntFF + T1STor + α11EHBond + α21EHBDesol
+ α31ESolEl + α41EHPhob + α5QSize
where: 1EIntFF is change in van der Waals interactions of ligand
and receptor and the internal force-field energy of the ligand,
T1STor is the change in free energy due to conformational
entropy and weighted (α1 − α5),1EHBond is the hydrogen bond
term, 1EHBDesol accounts for the disruption of hydrogen bonds
with solvent, 1ESolEl is the solvation electrostatic energy change
upon binding, 1EHPhob is the hydrophobic free energy gain and
QSize is the ligand size correction term.
Preparation of the EthR and InhA Proteins
for Docking
We extracted the crystal structure ofM. tuberculosis EthR bound
to the inhibitor BDM31369 (PDB code: 3Q0V, resolution 1.95 Å)
from the Protein DataBank in Europe (PDBe). The structure is
one of the EthR structures containing synthetic inhibitors that
occupy the allosteric pocket. The structure is dimeric and consists
of chain A with 188 ordered residues and chain B containing 194
ordered residues, bound to the inhibitor BDM31369 (PDBE code;
LL4). Some of the key residues interacting with the ligand include
L87, I107, F110, M142, Y148, T149, V152, N176, and W207.
Based on the structure validation from PDBe, chain Awith higher
quality backbone and side chain geometry percentiles, was used
in our docking calculations. Using standard ICM-docking (Neves
et al., 2012) receptor preparation tools the EthR structure was
prepared by deleting all water molecules, adding and optimizing
hydrogen atoms, adding missing heavy atoms, and adjusting
amide groups. The “setup receptor” tool was used to generate
receptor maps that cover the entire binding pocket of EthR using
the crystallized ligand to determine the grid center, a grid size
of 0.5 Å, and grid dimensions (x, y, z) of 51, 43, and 40 Å.
The performance of the docking procedure was evaluated by
redocking the co-crystallized ligand at thoroughness value of 1,
which regenerated the crystal conformation at root mean square
deviation (RMSD) of 1.81 Å between the Cα atoms of the docked
and the co-crystallized ligands. This proved that the software
regenerated the crystal structure conformation and accurately
docked the ligand.
Similarly, we extracted the 3D coordinates of an InhA
structure in complex with the inhibitor PT92 (PDBe code: 4OHU,
resolution of 1.6 Å) with the best structure-quality score from
the PDBe. In the presence of the co-factor, NAD, the inhibitor
occupies the substrate-binding pocket and primarily interact with
residues L218, A157, M199, M161, Y158, and the nicotinamide
moiety of NAD. The structure is tetrameric each chain with 289
residues and chains A, B, and C had percentiles of 100%. Chain
A was used in the docking calculations. ICM molecules were
generated using the ICM-docking receptor tools to generate grid
maps of dimensions (x, y, z) 49, 46, and 44 Å, using grid step of
0.50 Å. After preparation of the crystal ligand, it was re-docked
into the binding site and its conformation was regenerated at root
mean square deviation of 0.86 Å between the Cα atoms of the
docked and co-crystal ligands.
Preparation of Small Molecules and
Docking
Three-dimensional coordinates of 776 anti-TB compounds were
generated using a Pipeline Pilot protocol. The molecules were
imported into ICM (Totrov and Abagyan, 1997), amide bonds
were fixed, hydrogen atoms were built and the structures
were converted into ICM molecules. The compounds were
docked into EthR and InhA using thoroughness/effort value
of 2 and other default ICM parameters. The ICM scores were
standardized by calculating the ligand efficiency indices (LEI),
defined as the ratio between the ICM score and the number of
heavy atoms for each docked molecule (Abad-Zapatero et al.,
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2010). Compounds with LEI ≥ 1.0 were retained for further
analysis for each target protein.
Compounds
All anti-tuberculosis phenotypic compounds used in this work
were provided by GSK TCAMS project, Spain, as 10 mM DMSO
solutions.
Bacterial Strains and Cloning
inhA and ethR genes were amplified from chromosomal
DNA of M. tuberculosis H37Rv DNA acquired from ATCC
(ATCC25618D-2) and cloned in a pET28a vector (Novagen),
modified with an N-terminal 6xHis-SUMO tag between
BamHI/HindIII sites and in pHAT5 vector (Peranen et al.,
1996) between BamHI/EcoRI sites, respectively. The resulting
constructs were confirmed by DNA sequencing and transformed
into E. coli BL21(DE3) strain (Invitrogen).
Recombinant Expression and Protein
Purification
E. coli BL21(DE3) transformed with inhA and ethR containing
plasmids cells were grown to mid-exponential growth phase
(OD610 = 0.8) in LB media (Invitrogen) containing 30 mg.l−1
kanamycin (inhA) or 100 mg.l−1 Ampicilin (ethR) at 37◦C.
Isopropyl β–D-1-thiogalactopyranoside (IPTG) was then added
at a final concentration of 0.5 mM to induce gene expression and
the temperature was lowered to 18◦C. EthR purification followed
the protocol previously described by us (Surade et al., 2014).
For InhA cells were harvested 18–20 h later by centrifugation
and re-suspended in 50 mM HEPES pH 7.5, 0.5 M NaCl, 10%
glycerol (w/v) and 20 mM imidazole with protease inhibitor
tablets (Roche), DNAseI and 5 mM MgCl2. Cells were lysed by
sonication and the cell lysate was centrifuged at 27,000 g for
30 min to remove cell debris. Recombinant InhA was purified
with a HiTrap IMAC Sepharose FF column (GE-Healthcare),
equilibrated with 50 mM HEPES pH 7.5, 0.5 M NaCl, 10%
glycerol (w/v), and 20 mM imidazole. Elution was performed in
the same buffer with 500 mM imidazole. Imidazole was removed
by dialysis into 50 mM HEPES pH 7.5, 0.5 M NaCl and 10%
glycerol (w/v) and SUMO tag was cleaved overnight at 4◦C by
adding Ulp1 Protease at 1:100 ratio. SUMO tag, Ulp1 protease
and uncleaved SUMO-InhA were removed with a HiTrap IMAC
Sepharose FF column (GE-Healthcare), equilibrated with 50
mM HEPES pH 7.5, 0.5 M NaCl, 10% glycerol (w/v), and 20
mM imidazole. Flow through containing InhA was collected,
concentrated and loaded in a Superdex 200 column equilibrated
with 50 mM HEPES pH 7.5, 150 mM NaCl, and 10% glycerol
(w/v). Fraction purity was determined by SDS-PAGE. The purest
fractions were pooled, concentrated to∼12mg.ml−1, flash frozen
in liquid nitrogen and stored at −80◦C. Protein concentration
was determined using the Bradford method.
Enzymatic Assays (InhA)
InhA activity was assessed by a spectrophotometric assay that
followed the oxidation of NADH at λ = 340 nm in the presence
of 2-trans-octanoyl-CoA. Compounds were dissolved in 100%
DMSO. The enzyme reaction contains 30 mM PIPES pH 7.5, 50
mM NaCl, 1% (v/v) DMSO and 0.1 mM EDTA. InhA (100 nM)
was pre-incubated for 10 min at room temperature with 0.25 mM
NADH and compounds at a final concentration of 100 µM in
150 µl reaction volume. The reaction is started by the addition
of 2-trans-octanoyl-CoA at a final concentration of 1.5 mM,
prepared as described previously (He et al., 2006). The reactions
were followed for 20 min using a spectrophotometer plate reader
(CLARIOstar—BMG LABTECH). Inhibition percentage was
calculated based on the initial rates of reaction. All experiments
were performed in triplicate.
Surface Plasmon Ressonance Assay (EthR)
The surface plasmon resonance (SPR) assay was performed
on a BIAcore T100 with a protocol similar to what was
previously described (Surade et al., 2014). Briefly, M.
tuberculosis ethA promoter DNA (106 bp) was amplified
with 5′-CGGTCATGGATCCACGCTATCAAC-3′ and 5′-biotin-
CTGACTGGCCGCGGAGGTGGT-3′ and immobilized in
a SA chip (GE Healthcare). A control DNA fragment from
pUC19 (113 bp) was amplified in a similar fashion. Biotinylated
DNA (promoter and control) was then flowed over different
channels and similar levels of resonance units (RUs) were
achieved. For the initial screening a single run was performed
for each compound. A 2 µM EthR solution was then incubated
individually with each of the compounds at 100 µM, in 2 mM
MgCl2, 10 mM TRIS/HCL pH 7.5, 200 mM NaCl, 0.1 mM
EDTA, and 2% DMSO and flowed over the chip at 20 µl/min
for 120 s. For dissociation 150 s were given using the same flow
rate. Binding was determined by subtracting the response of the
control channel from the experimental channel at steady-state.
Regeneration of the chip was performed between samples by
flowing 0.03% SDS in running buffer for 60 s at 20 µl/min. To
calculate IC50, EthR-DNA-binding response, in the presence of
compounds, was measured at several compound concentrations
between (0.78 and 100 µM). Data were analyzed in Prism 5
(Graphpad software) and IC50 were calculated using a non-linear
regression model. Dose response experiments were performed in
triplicate.
Crystallization
EthR crystallization and compound soaking of crystals was
carried out as previously described (Surade et al., 2014). An
exception to this was compound 3 where co-crystallization was
required. For this purpose EthR at 20 mg.ml−1 was incubated
for 30 min on ice with 1 mM compound and 10% DMSO. Co-
crystallization was performed at 18◦C, using the sitting drop
method and several commercial crystallization screens were
tested (PEG I, (Qiagen); JCSG-plus, PACT, wizard classic I&II
and III&IV (Molecular Dimensions). The highest diffracting
condition for compound 3 was found in PACT crystallization
screen solution E12 (0.2 M sodium malonate dibasic and 20%
PEG 3350) using 0.3 µl EthR-compound 3 solution and 0.6
µl reservoir solution. All the other compounds that were co-
crystallized with EthR did not yield crystals or the crystals
diffracted only at low resolution. A cryogenic solution was
prepared by adding ethylene glycol up to 25% v/v to mother
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liquor. Crystals were briefly transferred to this solution, flash
frozen in liquid nitrogen and stored for data collection.
Data Collection, Structure Solution, and
Refinement
All data sets were collected at stations I02, and I04, at Diamond
Light Source (Oxford, UK). Data collection and refinement
statistics are summarized in Table S1.
Diffraction data were indexed, integrated, and reduced using
autoPROC from Global Phasing Limited (Vonrhein et al., 2011).
Molecular replacement was performed with Phaser (McCoy et al.,
2007) using PDB structure 1T56 as a search model. Refinement
was carried out iteratively with PHENIX (Adams et al., 2010)
and Coot (Emsley et al., 2010), and ligand and water fitting was
performed with Coot (Emsley et al., 2010).
RESULTS AND DISCUSSION
Predicted M. tuberculosis Targets
We initially predicted 1,462 human and bacterial potential targets
for the 776 GSK anti-TB compounds using theMultiple Category
FIGURE 1 | Number of ligands predicted to inhibit EthR (A) and InhA (B) using MCNBC, SEA, and docking calculations. A total of 28 and 15 compounds were jointly
identified by the three methods for EthR and InhA respectively. (C) Out of 35 compounds tested for against EthR using Surface Plasmon Resonance (SPR), 25
exhibited at least 50% inhibition of the enzyme, with four compounds showing 100% inhibition at 100 µM. (D) The complementary effect of MCNBC and docking
methods. The two methods successfully identified 19/25 inhibitors of EthR at Z-score and Ligand Efficiency Index cut-offs of 1 for MCNBC and Docking respectively
(broken lines).
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Naive Bayesian Classifiers (MCNBC). Each potential target
displayed positive Bayesian scores (NB) and standard deviation
scores (Z-scores) ≥ 1.5 for respective ligands. In this predicted
target set, 146 (10%) were bacterial proteins and 25 of these were
M. tuberculosis proteins, which were assigned to 132 compounds.
To obtain a wider coverage and possibly identify novel targets,
we mapped functional data and chemical bioactivity data of all
predicted human and bacterial targets across theirM. tuberculosis
orthologs as reported in the OrthoMCL database (Chen et al.,
2006). This increased the number of predicted M. tuberculosis
targets to 137 (Figure 1) for 517 compounds, and accounted
TABLE 1 | Target prediction according to functional category.
Functional category Number of proteins
DNA replication, recombination, and repair 10
Transcription 2
Ribosome and translation 7
Post-translational modification, protein degradation,
and chaperones
10
Signal transduction 2
Detoxification and defense 5
Energy production 11
Cell envelope biogenesis 8
Nucleotide metabolism 13
Amino acid metabolism 10
Co-factor metabolism 7
Lipid Metabolism 33
Inorganic ion metabolism 3
Secondary metabolites biosynthesis and catabolism 15
General function prediction 18
Unknown function 7
for 4,575 target-ligand pairs (Table S2A). Similarly, the second
ligand-based method, SEA generated 36,607 target-ligand pairs
for 1,346 proteins from all the organisms in ChEMBL version
16. After considering theM. tuberculosis orthologs in OrthoMCL,
110 targets were assigned to 428 compounds to give 1225 target-
ligand pairs (Table S2B).
The predicted M. tuberculosis protein targets are involved in
many known essential biological processes, with lipidmetabolism
having the highest number of predictions (Table 1). Although
∼5% of the predicted protein targets for these compounds are
established as essential for M. tuberculosis (Tables S2A,B), many
others are not. Nevertheless, all compounds are predicted to
hit multiple proteins with at least one essential protein per
compound that could account for the observed compound
activity in the phenotypic screen. Top predicted essential protein
targets include many enzymes involved in lipid biosynthesis such
as Pks13 (Rv3800c), a polyketide synthase involved in mycolic
acid biosynthesis (Gavalda et al., 2009) and InhA (Rv1484) an
anti-TB target of the approved drugs isoniazid and ethionamide,
both part of the FASII system. Amongst the several non-essential
proteins, is EthR (Rv3855) that is involved in ethionamide
resistance (Tables S2A,B). For these reasons, we selected InhA
and EthR to validate further the computational predictions.
As aforementioned, targeting EthR presents a potential way
to “boost” the anti-TB activity of ethionamide (Willand et al.,
2009).
EthR and InhA Inhibitors
Chemogenomic Predictions
The mycobacterial HTH-transcriptional regulator (EthR) has
been reported to be a facilitator for the resistance of the
TABLE 2 | Inhibition, IC50 values, MIC, ligand efficiency (LE), and PDB codes for inhibitors 1–7, 10, 12, and 19.
Compound Inhibition (100 µM) (%) IC50 IC50 95% confidence interval MIC
# (µM) LE Structure
1
GSK1107112a
100 12 11–13 8.6 0.35 PDB code
5MXV
2
GSK1570606a
100 9.9 8.2–12 9.3 0.31 PDB code
5MYL
3
GSK2032710a
100 3.9 3.3–4.6 4.2 0.24 PDB code
5MYM
4
GSK735826a
100 13 11–15 2.7 0.28 Not
obtained
5
GSK445886a
99 30 22–41 5.9 0.34 PDB code
5MYN
6
GSK735816a
97 22 20–25 2.3 0.30 PDB code
5MYR
7
GSK920684a
93 50 25–101 3.5 0.26 PDB code
5MYS
10
GSK921295a
74 * * 8.7 PDB code
5MYT
12 SB-
435634
67 * * 1.8 PDB code
5MYW
19
GSK2157753a
58 45 42–48 8.3 0.28 Not
obtained
*IC50 for these compounds was not possible to obtain in the tested conditions due to solubility issues. #MIC data was published before (Ballell et al., 2013).
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second-line tuberculosis drug, ethionamide. The protein was
amongst the M. tuberculosis proteins with the most compound
predictions having 90 assigned ligands using both MCNBC and
SEA (Figure 1A). EthR binding tunnel is a hydrophobic cavity
with multiple aromatic residues decorating its surface and a few
charged residues making it a promiscuous binding site known
to bind molecules with different properties (Willand et al., 2009,
2010; Flipo et al., 2012; Surade et al., 2014; Villemagne et al., 2014;
Nikiforov et al., 2016, 2017). It also possesses multiple hotspots
regions were fragments bind (Surade et al., 2014; Villemagne
et al., 2014; Nikiforov et al., 2016, 2017). It is therefore not
surprizing that this protein had a high number of predicted
inhibitors as these characteristics make this site promiscuous.
Extensive studies have already been performed on this protein.
In excess of 20 crystal structures of EthR in complex with
allosteric inhibitors have been reported. However, none of these
have reached Phase I clinical trials, and therefore the hunt for
inhibitors is still ongoing.
To complement the ligand-based predicted ligands for EthR,
we used ICM dock (Neves et al., 2012) to dock all the 776 TCAMS
compounds to a previously prepared crystal structure of M.
tuberculosis EthR bound to an inhibitor BDM31369 (PDB code:
3Q0V). Most compounds docked into the long hydrophobic
pocket of EthR and formed interactions with the side chains
of W103, W207, and F110 residues and hydrogen bonds with
N176 and N179. After ranking the compounds based on their
calculated ligand efficiency index (LEI), 200 potential inhibitors
displaying LEI greater than or equal to 1.0 were selected
for further analysis. Three potential inhibitors of EthR were
jointly predicted by the three complementary chemogenomic
approaches, 23 compounds were identified by MCNBC and
docking calculations whilst MCNBC/SEA and SEA/DOCKING
each had one common compound (Figure 1A).
The clinical utility of the first-line anti-TB drug isoniazid
(INH) against the enoyl acyl protein reductase InhA, is being
challenged by the increasing drug resistance attributed to
FIGURE 2 | Surface plasmon resonance dose response curves for EthR inhibitors.
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mutations or deletions in the active site of katG gene, which
encodes catalase-peroxidase KatG, an enzyme responsible for the
metabolic activation of INH (Vilcheze and Jacobs, 2014). For
this reason, it is imperative to identify new drugs that target
InhA but circumvent the KatG activation pathway. We used
the chemogenomic methods MCNBC and SEA to synergistically
allocate more than 80 as potential inhibitors of InhA. From
the docking calculations 159 compounds displayed LEI ≥ 1.0
indicating favorable binding affinity to InhA (Figure 1B). Even
though no compounds were jointly predicted by all three
methods, about 15 compounds were commonly predicted by
either docking and SEA, MCNBC, and docking or MCNBC and
SEA approaches.
From the predicted EthR inhibitors, we selected a set of 26
compounds (1–16, 19, 24–26, 28–29, and 31–34), that were
identified by one or more of the computational methods above,
and for which physical samples were available for use in the
in vitro assays. Approximately one third of these compounds
displayed Z-scores ≥ 1.00 indicating similar structural features
to those previously reported for EthR ligands in our training
set. To investigate the ability of the chemogenomic methods
to distinguish between true and false negatives our second set
contained 9 compounds (17–18, 20–23, 27, 30, and 35) from the
776 GSK-TCAMS dataset, that fell outside the selection criteria
and represent different molecular clusters. The target prediction
scores for the 35 compounds are given in Table S3. About 51%
(17 compounds) of this set was predicted to inhibit both EthR
and InhA using both ligand-based and structure-based methods.
Hence, in vitro experiments were also performed to confirm the
activities of the 35 compounds against InhA.
Validation of EthR Inhibitors
A single compound concentration run at 100 µMwas performed
using SPR to evaluate the inhibitory effect of individual
compounds in EthR binding to DNA (Table S2A). From this
run we could immediately observe that the 71% (25/35) of the
compounds were active against EthR (> 50% inhibition) and
that compounds that were outside the selection criteria all had
low activities (inhibition < 60%), (Figures 1C,D), confirming
that these computational methods can distinguish true and
false negatives. The top 20 compounds were then selected to
determine IC50 values (Table 2 and Figure 2). Amongst these
were compounds 1, 5, 8, 10, 12, and others identified solely from
docking calculations, illustrating the complementarity of ligand-
based and structure-based methods (Figures 1C,D). Eight of the
tested compounds had an IC50 lower than 50 µM while for the
others, accurate IC50 values were not possible to obtain due to
solubility issues in the tested assay conditions. We then managed
to obtain X-ray crystal structures for compounds 1, 2, 3, 5, 6, 7,
10, and 12 bound to EthR (Figures 3, 4). Omit maps for each of
the ligands is available in Figure S1.
FIGURE 3 | X-ray crystal structures of EthR:inhibitor complexes showing binding cavity surface and binding modes of the ligands. Numbers reflect the respective
compounds. Figures were made using Pymol.
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FIGURE 4 | X-ray crystal structures showing interactions maps between EthR and inhibitors. Red disks represent hydrogen bonds, blue dots halogen bonds, gray
disks depict pi-pi interactions, green disks hydrophobic interactions, yellow disks suphur-pi and carbon-pi interactions, pink disks donor-pi interactions, orange disks
cation-pi interactions and cyan dots carbonyl interactions. Interactions were calculated using Intermezzo plugin for Pymol (Ochoa et al. unpublished). The carbonyl
groups highlighted in red form hydrogen bonds with asn176 and are a common feature in many published EthR inhibitors. The common substructure
(4-(pyridine-2-yl)thiazole) is highlighted in blue.
EthR binding site is characterized by a long hydrophobic
tunnel surrounded mostly by hydrophobic residues, many of
which are aromatic, plus four polar amino acids and a basic
residue (Dover et al., 2004). The interactions of our compounds
with EthR were dominated pi–pi interactions with (W103, F110,
F114, W138, W145, Y148, F184, and W207, although hydrogen
bonds were also present, with all but compound 3 forming
at least one hydrogen bond with one of the polar residues
(T149, N176, and N179) as seen in Figure 4. Other interactions
such as hydrogen donor-pi or cation-pi (observed in compound
1 (F110), 3 (Q125), 5 (F110), 10 (F110), and 12 (W103), sulfur-
pi (observed in compound 10withM142), carbon-pi (observed in
compound 2, 3 and 7), and halogen bond (observed in compound
1 with T149) were also present but less prevalent (Figure 4).
Hydrophobic interactions, extending fromW103 at the entrance
of the binding site to W138 at the inner hydrophobic site are
also observed for many of the compounds (Figure 4). This dense
network of protein-ligand interactions appears to stabilize the
conformational changes in EthR and inhibition of DNA binding
observed by SPR. Interestingly six of the best compounds (2,
4, 5, 6, 7, 10) share a common substructure composed by a
4-(pyridine-2-yl)thiazole (Figure 4), that for compounds 2, 5,
and 7 occupies the same part of EthR binding site forming
pi-interactions with F110, W103, Y148, and W207, while for
compounds 6 and 10 the same substructure forms pi-interactions
with F110, F114, W138, W145, and F184 (Figure 4). Another
common feature shared between several of the compounds (1,
2, 3, 7, and 10) is the presence of a ketone that forms a hydrogen
bond with N176 in all but compound 3. This ketone is a feature
shared by many other EthR binding compounds reported in
the literature (Figure 4 and Figure S2). Although we did not
obtain a structure for one of the most potent EthR inhibitors
identified in this work (compound 4, IC50 ≈ 13 µM) (Table 2),
it is quite likely that this compound, like others reported here,
interacts with EthR by forming similar interactions at the binding
site.
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FIGURE 5 | (A) Three inhibitors exhibited dual inhibitory activity against EthR and InhA. (B) Heatmap displaying the other M. tuberculosis essential proteins predicted
using MCNBC for the top 8 EthR inhibitors.
Validation of InhA Inhibitors
To assess whether the predicted compounds are active against
InhA, an enzymatic assay was performed with compounds tested
at a single concentration of 100 µM. Only compounds 1, 7, and
8 showed inhibition greater than 40% (Figure 5A). IC50s were
not possible to calculate due to solubility issues in the required
assay conditions. An attempt to address this issue by increasing
DMSO concentration, to improve compound solubility, led to
very low enzymatic activity that prevented obtaining reliable
data.
Dual Activity against EthR and InhA
The computational target prediction approaches described here
have highlighted the possibility of inhibiting two or more M.
tuberculosis proteins by one of the phenotypic hits. Amongst
the 35 compounds selected for in vitro assays against EthR, 17
compounds were also predicted to hit InhA. Three compounds
displayed inhibitory activity against both EthR and InhA
(Figure 5A). Compound 1 is active against both EthR (IC50 ≈12
µM) and InhA (62% inhibition at 100µM) (Table 2), confirming
the computational predictions. Interestingly, this compound was
identified solely from structure-based predictions. Even though
an attempt to obtain a co-crystal structure of the compound
with InhA was unsuccessful, the docking LEI values for the
compound to both enzymes (EthR: 1.58 and InhA: 1.11) indicate
high binding affinity. The EthR-compound 1 co-crystal structure
confirms the occupancy of the compound in the EthR binding
site.
Although targeting EthR has been reported to boost the
activity of the second-line drug ethionamide against InhA
(Willand et al., 2009), EthR itself is not an essential protein and
compounds that solely hit EthR will not show sterilizing activity
without the concomitant use of ethionamide. Furthermore, the
dual activity compounds reported here, are not sufficiently potent
in vitro inhibitors of InhA to explain their observed MIC
value. This indicates that although many of our predictions
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were confirmed, the reasons behind whole cell activities of the
compounds most likely lie elsewhere.
Interestingly some of the compounds reported here have
chemical groups that are known to be modified by EthA.
Thiophenes and thioethers are present in compounds 1, 8, and
10 and are known to be substrates for EthA (Mori et al., 2015;
Grant et al., 2016). Furthermore, EthA was found to have a
much wider substrate preference than initially thought and is
known tomodify also thiocarbamides and thioureas (Dover et al.,
2007; Nishida and Ortiz de Montellano, 2011; Gopal and Dick,
2015; Grzegorzewicz et al., 2015). Although speculative it is
possible that these compounds hit EthR but are also pro-drugs
that are activated by EthA self-increasing their own activation
by raising the levels of EthA available inside M. tuberculosis and
subsequently hitting other targets.
A more conservative explanation is that the observed MICs
are explained by a direct dual or polypharmacology by hitting
other M. tuberculosis targets. To that effect, the heatmap in
Figure 4 displays the 16 essential M. tuberculosis proteins
predicted for eight EthR inhibitors (compounds 2, 4, 5, 6, 7,
10, 12, and 19) using ligand-based approach. The other three
inhibitors, 1, 3, and 8 were identified through a structure-based
approach, hence are not shown in Figure 4. We observe that each
compound has the potential to hit at least one essential protein,
with MapA assigned for all but compound 12 (Figure 5B) and
compound 19 potentially targeting 10 proteins. Furthermore,
compounds 5 and 12 selected for both EthR and InhA from the
structure-based predictions were assigned to further essentialM.
tuberculosis proteins by the ligand-based MCNBC method. A
summary of the all the other predicted M. tuberculosis proteins
for these compounds is given in Table S4. However, it is also
possible that the observed MIC values are a result of a synergistic
effect that also includes their activities against InhA and EthR and
on other enzyme(s).
A designed multi-targeted approach in drug discovery has
been attracting attention in recent years, with large scale
functional genomics studies in several model organisms. Many
single gene knockouts by themselves show no, or small,
phenotypic effect with as little as ∼19% of the genes being
essential in a number of model organisms (Hopkins, 2008).
Compounds that hit multiple targets have the capacity to explore
synthetic lethal interaction that further expand the number
of available targets in an organism (Hopkins, 2008). The fact
that many of these compounds show strong EthR inhibition
together with very goodMIC values raises the prospect of further
enhancing ethionamide killing effect with a combined therapy
that uses an ethionamide boosting compound that also kills M.
tuberculosis by hitting one or more enzymes.
Several other TB drugs thiacetazone, thiocarlide (isoxyl),
and the recently developed perchlozone have been shown to
be activated by EthA and hit the same target, HadABC, a
group of enzymes involved in mycolic acid synthesis (Gopal
and Dick, 2015; Grzegorzewicz et al., 2015). Thiacetazone use
has declined due to severe and sometimes fatal side effects
(Miller et al., 1972), and isoxyl is no longer used because of
failures in clinical outcomes due to its low plasma concentrations
(Wang et al., 2012). Potentiating the activation of these drugs
by increasing the amount of EthA available in the cells with
EthR inhibitors might allow some of these drugs to be viable in
modern TB chemotherapy by lowering the dosage required to
kill M. tuberculosis. Perchlozone is a new TB drug approved in
the Russian Federation to treat MDR-TB. Again, EthR inhibitors
may potentiate the killing effects of this drug by increasing
the amount of EthA available making it a much stronger
anti-TB drug.
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